IPO's: Looking for Bargains

2017 is shaping up to be a pretty busy year for initial public offerings (IPOs). Through June 30, 2017, there were 77 IPOs, raising a total of $20.5 billion, according to Renaissance Capital, a firm that tracks IPOs. This compares to only 42 deals that raised $6.2 billion in last year’s first half. The total capital raised year-to-date is already higher than all of last year. Also, activity is on track to beat last year’s 105 IPOs, although it is likely to be below the annual average of 168 deals since 2010.

What’s driving the renewed interest? Much of the credit goes to the enduring strength of the bull market. Investors are clamoring for equities, particularly those with open-ended growth prospects and potentially rapid price gains. Nearly half of the recent IPOs are in the healthcare/biotech and technology sectors, many of which produced very strong gains out of the gate. For example, UroGen Pharma has gained 84% since its offering in May. Broadly, most IPOs have produced good returns, reflecting the market’s enthusiasm.

Not all deals have been blockbusters: Blue Apron’s IPO in late June turned sour, with its share price down 35% (because of concerns that it is increasingly vulnerable to competition from companies like Amazon). Snapchat parent Snap’s debut has produced a 15% loss so far. Both companies are generating ever-larger operating losses with little chance of improvement--in effect, growing their revenues by selling their services below cost. Along with FitBit (down 72%) and GoPro (down 66%), these deals indicate to us that the market continues to show some discipline.

While many of the newly-public biotech and technology companies no doubt sell interesting products and services, their strong share price momentum and high valuations put them outside of our contrarian focus--and we suspect may not be sustainable. We sifted through the roster of IPOs since the beginning of 2016 looking for stocks that investors have bypassed. Often, if a company trades below its IPO price, called “breaking its deal price,” the market will thereafter shun the stock on that basis alone. Our August 2017 Turnaround Letter details six recent IPOs by companies with worthwhile products and services, reasonable valuations and share prices below or little-changed from their debut prices.

More Turnaround Tips

Identify & Profit from Distressed Investing

Free Report: Turnaround Investing Mistakes

Turnaround Investing Blog

Turnaround Investing Blog

Turnaround Investing Philosophy: 32 Years Later, Some Things Never Change

Recently I was asked how my investing perspective changed over the 32 years of publishing The Turnaround Letter. It's a fascinating question because change is constant, and often beneficial (although that's not a given) in the business world. If change is the norm, can investing principles stay constant? I firmly believe that they can. Read More.

EV/EBITDA: What Is It & Why Are We Using It More?

In reading recent editions of The Turnaround Letter, you have probably noticed that we are increasingly using EV/EBITDA as a valuation measure, rather than the better-known price/earnings multiple.  We thought it might be useful to describe this measure and why we like it.

Read More.

Turnaround Letter Stock Pick Named Top Performer of 2017

 

stock market advicex

 

What Last Year's Top Stock Pickers Are Buying in 2018

 

This Forbes write-up follows up on the recent Top Stock Tips report--naming The Turnaround Letter's Crocs recommendation the top performer of 2017: With 90% gains, CROX beat out 100 other investment ideas included in the report; and the stock continues to have value investing appeal, according to Putnam.

 

George notes, "We see additional upside for the stock in 2018 as management's efforts continue to bear fruit, though the gains will likely be more muted than we saw in 2017."